Published in Annu Rev Immunol on January 01, 1983
Virulence of enterococci. Clin Microbiol Rev (1994) 4.32
Infectious diseases associated with complement deficiencies. Clin Microbiol Rev (1991) 4.01
Macrophage heterogeneity in the rat as delineated by two monoclonal antibodies MRC OX-41 and MRC OX-42, the latter recognizing complement receptor type 3. Immunology (1986) 3.69
Poxvirus pathogenesis. Microbiol Rev (1991) 3.54
Inherited deficiency of the Mac-1, LFA-1, p150,95 glycoprotein family and its molecular basis. J Exp Med (1984) 3.14
Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Infect Immun (1992) 2.73
Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J Exp Med (1996) 2.67
Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody. J Exp Med (1983) 2.31
Human C3b/C4b receptor (CR1). Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristics of C3/C4 binding proteins. J Exp Med (1987) 2.28
gp140, the C3d receptor of human B lymphocytes, is also the Epstein-Barr virus receptor. Proc Natl Acad Sci U S A (1985) 2.07
Identification of a partial cDNA clone for the human receptor for complement fragments C3b/C4b. Proc Natl Acad Sci U S A (1985) 1.81
Identification of a restriction fragment length polymorphism by a CR1 cDNA that correlates with the number of CR1 on erythrocytes. J Exp Med (1986) 1.56
Analysis of C3-receptor activity on human B-lymphocytes and isolation of the complement receptor type 2 (CR2). Biochem J (1984) 1.51
Isolation of complement-fragment-iC3b-binding proteins by affinity chromatography. The identification of p150,95 as an iC3b-binding protein. Biochem J (1985) 1.49
Complement mediates human immunodeficiency virus type 1 infection of a human T cell line in a CD4- and antibody-independent fashion. J Exp Med (1991) 1.44
Identification of a partial cDNA clone for the C3d/Epstein-Barr virus receptor of human B lymphocytes: homology with the receptor for fragments C3b and C4b of the third and fourth components of complement. Proc Natl Acad Sci U S A (1986) 1.42
Streptococcus pneumoniae capsular serotype 19F is more resistant to C3 deposition and less sensitive to opsonophagocytosis than serotype 6B. Infect Immun (2008) 1.33
Candida mannan: chemistry, suppression of cell-mediated immunity, and possible mechanisms of action. Clin Microbiol Rev (1991) 1.32
Antigen-bound C3b and C4b enhance antigen-presenting cell function in activation of human T-cell clones. Immunology (1988) 1.30
Naturally occurring anti-band-3 antibodies and complement together mediate phagocytosis of oxidatively stressed human erythrocytes. Proc Natl Acad Sci U S A (1987) 1.23
Substitution of a single amino acid (aspartic acid for histidine) converts the functional activity of human complement C4B to C4A. Proc Natl Acad Sci U S A (1990) 1.17
Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement. Proc Natl Acad Sci U S A (1985) 1.16
Structure of the human CR1 gene. Molecular basis of the structural and quantitative polymorphisms and identification of a new CR1-like allele. J Exp Med (1989) 1.15
The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood (2006) 1.09
The capsular serotype of Streptococcus pneumoniae is more important than the genetic background for resistance to complement. Infect Immun (2010) 1.05
Isolation of follicular dendritic cells from human tonsils and adenoids. III. Analysis of their Fc receptors. Immunology (1985) 1.05
Interaction of pneumococcal histidine triad proteins with human complement. Infect Immun (2010) 1.05
Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions. J Exp Med (1990) 1.03
Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b. J Clin Invest (1985) 1.01
The role of complement, platelet-activating factor and leukotriene B4 in a reversed passive Arthus reaction. Br J Pharmacol (1992) 0.98
Complement activation and C3 binding by serum-sensitive and serum-resistant strains of Pseudomonas aeruginosa. Infect Immun (1989) 0.97
Large-scale isolation of complement receptor type 1 (CR1) from human erythrocytes. Proteolytic fragmentation studies. Biochem J (1985) 0.97
Complement-dependent cellular cytotoxicity: lymphoblastoid lines that activate complement component 3 (C3) and express C3 receptors have increased sensitivity to lymphocyte-mediated lysis in the presence of fresh human serum. Proc Natl Acad Sci U S A (1985) 0.95
Stimulation of complement component C3 synthesis in macrophagelike cell lines by group B streptococci. Infect Immun (1987) 0.90
Mapping of the properdin-binding site in the third component of complement. Biochem J (1984) 0.89
Phenotypic analysis of complement receptor 2+ T lymphocytes: reduced expression on CD4+ cells in HIV-infected persons. Immunology (1992) 0.87
Release of prostaglandin E and thromboxane from macrophages by stimulation with factor H. Clin Exp Immunol (1984) 0.86
Decay-accelerating factor is present on paroxysmal nocturnal hemoglobinuria erythroid progenitors and lost during erythropoiesis in vitro. J Exp Med (1985) 0.86
Functional analysis and quantification of the complement C3 derived anaphylatoxin C3a with a monoclonal antibody. Clin Exp Immunol (1987) 0.84
Terminal complement component deficiencies and rheumatic disease: development of a rheumatic syndrome and anticomplementary activity in a patient with complete C6 deficiency. Ann Rheum Dis (1985) 0.83
Evaluation of the contribution of multiple DAMPs and DAMP receptors in cell death-induced sterile inflammatory responses. PLoS One (2014) 0.81
Metabolites of procainamide and practolol inhibit complement components C3 and C4. Biochem J (1988) 0.81
Matrix metalloproteinase-2, -9 and -13 are involved in fibronectin degradation of rat lung granulomatous fibrosis caused by Angiostrongylus cantonensis. Int J Exp Pathol (2007) 0.81
Increased C3 production in human monocytes after stimulation with Candida albicans is suppressed by granulocyte-macrophage colony-stimulating factor. Infect Immun (1993) 0.81
Cloning and functional expression of the canine anaphylatoxin C5a receptor. Evidence for high interspecies variability. Biochem J (1992) 0.81
Membrane-bound C4b interacts endogenously with complement receptor CR1 of human red cells. J Exp Med (1986) 0.80
Peripheral catabolism of CR1 (the C3b receptor, CD35) on erythrocytes from healthy individuals and patients with systemic lupus erythematosus (SLE). Clin Exp Immunol (1992) 0.80
Opsonized streptococcal cell walls cross-link human leukocytes and erythrocytes by complement receptors. Infect Immun (1985) 0.80
Pathogenesis of B-cell superantigen-induced immune complex-mediated inflammation. Infect Immun (2006) 0.79
Amino acid sequence of the trypsin-generated C3d fragment from human complement factor C3. Biochem J (1985) 0.78
Hagfish humoral defense protein exhibits structural and functional homology with mammalian complement components. Proc Natl Acad Sci U S A (1992) 0.78
Vitronectin-binding staphylococci enhance surface-associated complement activation. Infect Immun (1997) 0.77
Generation of the bioactive kallikrein-derived fragment, C3d-k, by HANE-plasma. Clin Exp Immunol (1985) 0.77
Histiocytosis-X cells express C3b, C3d, and C3bi receptor (CR1, CR2, and CR3) antigens. Arch Dermatol Res (1985) 0.77
The genetics of Alzheimer's disease. Scientifica (Cairo) (2012) 0.76
Specificity of bovine serum antibody to capsular carbohydrate antigens from Pasteurella haemolytica. J Clin Microbiol (1990) 0.75
Red cell associated, naturally occurring anti-spectrin antibodies. Clin Exp Immunol (1987) 0.75
Molecular structure and expression of anthropic, ovine, and murine forms of complement receptor type 2. Clin Vaccine Immunol (2008) 0.75
Differential complement activation pathways promote C3b deposition on native and acetylated LDL thereby inducing lipoprotein binding to the complement receptor 1. J Biol Chem (2014) 0.75
Human ICE/CED-3 protease nomenclature. Cell (1996) 7.11
Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A (1976) 6.65
Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci U S A (1984) 6.62
Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J Exp Med (1980) 6.49
Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol (1982) 5.44
Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc Natl Acad Sci U S A (1977) 5.23
Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc Natl Acad Sci U S A (1979) 5.08
Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature (1996) 4.92
Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med (1975) 4.69
Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science (1990) 4.67
Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway. Proc Natl Acad Sci U S A (1978) 4.43
C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science (1996) 4.35
Substrate specificities of caspase family proteases. J Biol Chem (1997) 4.16
Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement. J Exp Med (1973) 3.83
Increased expression of C3b receptors on polymorphonuclear leukocytes induced by chemotactic factors and by purification procedures. J Immunol (1983) 3.79
Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J Immunol (1979) 3.50
Mode of inheritance of decreased C3b receptors on erythrocytes of patients with systemic lupus erythematosus. N Engl J Med (1982) 3.40
Properdin factor D: characterization of its active site and isolation of the precursor form. J Exp Med (1974) 3.21
Proteolytic activation of protein kinase C delta by an ICE-like protease in apoptotic cells. EMBO J (1995) 3.16
Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins. J Exp Med (1977) 2.87
Action of the C3b-inactivator on the cell-bound C3b. J Immunol (1979) 2.81
CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science (1992) 2.79
Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes. Proc Natl Acad Sci U S A (1984) 2.71
Sequences capable of restoring poly(A) site function define two distinct downstream elements. EMBO J (1986) 2.69
A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science (1995) 2.68
C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol (1976) 2.64
Activation of the properdin pathway of complement in patients with gram-negative of bacteremia. N Engl J Med (1975) 2.63
Membrane distribution and adsorptive endocytosis by C3b receptors on human polymorphonuclear leukocytes. J Exp Med (1981) 2.33
Human C3b/C4b receptor (CR1). Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristics of C3/C4 binding proteins. J Exp Med (1987) 2.28
Properdin: initiation of alternative complement pathway. Proc Natl Acad Sci U S A (1975) 2.20
Properdin factor D. II. Activation to D by properdin. J Exp Med (1974) 2.19
Purification of C3b inactivator and demonstration of its two polypeptide chain structure. J Immunol (1977) 2.16
Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv Immunol (1989) 2.15
Genetic regulation of a structural polymorphism of human C3b receptor. J Clin Invest (1983) 2.07
Current concepts in immunology: the alternative pathway of complement--a system for host resistance to microbial infection. N Engl J Med (1980) 2.07
A complement receptor locus: genes encoding C3b/C4b receptor and C3d/Epstein-Barr virus receptor map to 1q32. J Immunol (1987) 1.94
Initiation of C3 cleavage in the alternative complement pathway. J Immunol (1975) 1.94
Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis. J Exp Med (1988) 1.92
Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19. J Exp Med (1991) 1.88
Suppression of signal transducer and activator of transcription 3-dependent B lymphocyte terminal differentiation by BCL-6. J Exp Med (2000) 1.87
A subpopulation of B220+ cells in murine bone marrow does not express CD19 and contains natural killer cell progenitors. J Exp Med (1996) 1.86
Identification of a partial cDNA clone for the human receptor for complement fragments C3b/C4b. Proc Natl Acad Sci U S A (1985) 1.81
CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase. Science (1993) 1.80
Tyrosine phosphorylation of phospholipase C induced by membrane immunoglobulin in B lymphocytes. Proc Natl Acad Sci U S A (1991) 1.78
Lateral distribution and diffusion of the C3b receptor of complement, HLA antigens, and lipid probes in peripheral blood leukocytes. Proc Natl Acad Sci U S A (1980) 1.78
Opsonin-independent phagocytosis of activators of the alternative complement pathway by human monocytes. J Immunol (1978) 1.71
Body composition during the first 2 years of life: an updated reference. Pediatr Res (2000) 1.64
Longitudinal assessment of energy balance in well-nourished, pregnant women. Am J Clin Nutr (1999) 1.64
Suppression of the immune response by a soluble complement receptor of B lymphocytes. Science (1991) 1.63
Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes. J Immunol (1988) 1.62
Deuterium and oxygen-18 measurements on microliter samples of urine, plasma, saliva, and human milk. Am J Clin Nutr (1987) 1.62
Oxygen isotope ratio measurements on carbon dioxide generated by reaction of microliter quantities of biological fluids with guanidine hydrochloride. Anal Chem (1987) 1.61
Randomised controlled trial of colloid or crystalloid in hypotensive preterm infants. Arch Dis Child Fetal Neonatal Ed (1997) 1.58
Identification of a restriction fragment length polymorphism by a CR1 cDNA that correlates with the number of CR1 on erythrocytes. J Exp Med (1986) 1.56
The role of antibody in the activation of the alternative complement pathway. Springer Semin Immunopathol (1983) 1.55
Monitoring childhood obesity: assessment of the weight/height index. Am J Epidemiol (1999) 1.54
Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b. J Exp Med (1979) 1.53
PMA induces the ligand-independent internalization of CR1 on human neutrophils. J Immunol (1985) 1.51
C3 requirements for formation of alternative pathway C5 convertase. J Immunol (1976) 1.50
Measurement of body water by multifrequency bioelectrical impedance spectroscopy in a multiethnic pediatric population. Am J Clin Nutr (1999) 1.50
Tissue-specific phosphorylation of complement receptors CR1 and CR2. J Exp Med (1986) 1.48
Structure of the human B lymphocyte receptor for C3d and the Epstein-Barr virus and relatedness to other members of the family of C3/C4 binding proteins. J Exp Med (1988) 1.48
Inhibition of the B cell by CD22: a requirement for Lyn. J Exp Med (1998) 1.48
The result of radical retropubic prostatectomy and adjuvant therapy for pathologic stage C prostate cancer. Int J Radiat Oncol Biol Phys (1996) 1.47
Validity of self-assessment of pubertal maturation in African American and European American adolescents. J Adolesc Health (1999) 1.44
Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytes. J Exp Med (1993) 1.44
Generation of C3a anaphylatoxin from human C3 by human mast cell tryptase. J Immunol (1983) 1.44
Body composition of a young, multiethnic female population. Am J Clin Nutr (1997) 1.43
Identification of a partial cDNA clone for the C3d/Epstein-Barr virus receptor of human B lymphocytes: homology with the receptor for fragments C3b and C4b of the third and fourth components of complement. Proc Natl Acad Sci U S A (1986) 1.42
Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus. Arthritis Rheum (1986) 1.41
Radiotherapy for isolated increases in serum prostate-specific antigen levels after radical prostatectomy. Mayo Clin Proc (1994) 1.40
Lipid monolayer-coated solid surfaces do not perturb the lateral motion and distribution of C3b receptors on neutrophils. J Cell Biol (1982) 1.40
Membrane sialic acid on target particles modulates their phagocytosis by a trypsin-sensitive mechanism on human monocytes. Proc Natl Acad Sci U S A (1978) 1.39
Energy expenditure and deposition of breast-fed and formula-fed infants during early infancy. Pediatr Res (1990) 1.39
Infant feeding mode affects early growth and body composition. Pediatrics (2000) 1.38
Isolation of alternative pathway C3 convertase containing uncleaved B and formed in the presence of C3 nephritic factor (C3neF). J Immunol (1976) 1.38
Characterization of a soluble form of the C3b/C4b receptor (CR1) in human plasma. J Immunol (1985) 1.38
Neutrophils express a receptor for iC3b, C3dg, and C3d that is distinct from CR1, CR2, and CR3. J Immunol (1985) 1.37
Seeking wisdom in innate immunity. Nature (1997) 1.37
A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations. Proc Natl Acad Sci U S A (1993) 1.36
Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2. J Exp Med (1989) 1.35
Characterization of human T lymphocytes that express the C3b receptor. J Immunol (1983) 1.35
Self-renewal of B-1 lymphocytes is dependent on CD19. Eur J Immunol (1996) 1.34
p65: A C3b-binding protein on murine cells that shares antigenic determinants with the human C3b receptor (CR1) and is distinct from murine C3b receptor. J Immunol (1985) 1.32
Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin. J Exp Med (1978) 1.32
The identification of N-linked oligosaccharides on the human CR2/Epstein-Barr virus receptor and their function in receptor metabolism, plasma membrane expression, and ligand binding. J Biol Chem (1985) 1.29
Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia (2001) 1.27
CD19 as a membrane-anchored adaptor protein of B lymphocytes: costimulation of lipid and protein kinases by recruitment of Vav. Immunity (1998) 1.25
Organization of the genes encoding complement receptors type 1 and 2, decay-accelerating factor, and C4-binding protein in the RCA locus on human chromosome 1. J Exp Med (1988) 1.25
Activation of the CPP32 protease in apoptosis induced by 1-beta-D-arabinofuranosylcytosine and other DNA-damaging agents. Blood (1996) 1.24
Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest (1981) 1.23